Cognition Therapeutics

brain pills alzheimers drug reaction down syndrome
Biotech

Cognition's phase 2 SHIMMER results allow dementia drug to shine

The phase 2 study in dementia with Lewy bodies met its primary endpoint of safety and tolerability, Cognition said.
James Waldron Dec 18, 2024 7:00am
brain alzheimers dementia neuroscience gears thought think

Cognition's phase 2 SHINE data tarnish Alzheimer's prospect

Jul 29, 2024 9:24am
amyloid plaque alzheimers brain

Cognition posts midphase brainwave data on Alzheimer's prospect

Jun 28, 2023 8:20am